Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNewAmsterdam Pharma Company N.V. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 0 | $0.00 | $0.00 | $0.00 |
NewAmsterdam Pharma Company N.V. Earnings Date And Information
NewAmsterdam Pharma Company N.V. last posted its earnings results on N/A. The company reported $N/A earnings per share for the quarter, missing analysts' consensus estimates of $N/A by $0. The company had revenue of 12.77 M for the quarter and had revenue of 45.56 M for the year. NewAmsterdam Pharma Company N.V. has generated $-3 earnings per share over the last year ($-2.56 diluted earnings per share) and currently has a price-to-earnings ratio of -9.58. NewAmsterdam Pharma Company N.V. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
NewAmsterdam Pharma Company N.V. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/26/2025 | Q4 2024 | N/A | -$0.98 | N/A | $1.62 M | $12.77 M |
| 11/06/2024 | Q3 2024 | N/A | -$0.18 | N/A | N/A | $29.11 M |
| 08/07/2024 | Q2 2024 | N/A | -$0.38 | N/A | N/A | $2.13 M |
| 05/08/2024 | Q1 2024 | N/A | -$0.98 | N/A | N/A | $1.30 M |
| 02/28/2024 | Q4 2023 | N/A | -$0.52 | N/A | N/A | $1.59 M |
| 09/29/2023 | Q3 2023 | N/A | -$0.56 | N/A | N/A | $1.88 M |
| 08/07/2023 | Q2 2023 | N/A | -$0.43 | N/A | N/A | $1.57 M |
| 08/07/2023 | Q1 2023 | N/A | -$0.47 | N/A | N/A | $7.96 M |
| 03/31/2023 | Q4 2022 | N/A | -$24.19 | N/A | N/A | $1.38 M |
| 11/28/2022 | Q3 2022 | N/A | -$23.19 | N/A | N/A | $5.62 M |
| 06/28/2022 | Q2 2022 | N/A | $0.75 | N/A | N/A | $46.75 M |
| 03/29/2022 | Q1 2022 | N/A | $0.75 | N/A | N/A | $46.75 M |
| 12/30/2021 | Q4 2021 | N/A | -$1.73 | N/A | N/A | $0 |
| 09/29/2021 | Q3 2021 | N/A | -$0.82 | N/A | N/A | $0 |
| 06/29/2021 | Q2 2021 | N/A | -$0.43 | N/A | N/A | $0 |
| 03/30/2021 | Q1 2021 | N/A | -$0.43 | N/A | N/A | $0 |
| 12/30/2020 | Q4 2020 | N/A | $0.00 | N/A | N/A | $0 |
| 09/29/2020 | Q3 2020 | N/A | -$0.02 | N/A | N/A | $0 |
| 06/29/2020 | Q2 2020 | N/A | -$0.02 | N/A | N/A | $0 |
| 03/30/2020 | Q1 2020 | N/A | -$0.02 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
NewAmsterdam Pharma Company N.V. Earnings: FAQ's
The conference call for NewAmsterdam Pharma Company N.V.'s latest earnings report can be listened to online.
The conference call transcript for NewAmsterdam Pharma Company N.V.'s latest earnings report can be read online.
NewAmsterdam Pharma Company N.V. (:NAMSW) has a recorded annual revenue of $45.56 M.
NewAmsterdam Pharma Company N.V. (:NAMSW) has a recorded net income of $-241,598,000.NewAmsterdam Pharma Company N.V. has generated $-2.56 earnings per share over the last four quarters.
NewAmsterdam Pharma Company N.V. (:NAMSW) has a price-to-earnings ratio of -9.58 and price/earnings-to-growth ratio is 0.43.